Alterity Therapeutics Ltd. ( (AU:ATH) ) has shared an announcement.
Alterity Therapeutics Limited has announced the issuance of 164,242,200 fully paid ordinary shares. The issuance was conducted without the need for a disclosure under Part 6D.2 of the Corporations Act, as the company has met all necessary compliance requirements. This move could potentially impact Alterity’s market standing and provides additional capital for its continued operations and development efforts.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases. The company is listed on both the Australian Securities Exchange (ASX: ATH) and NASDAQ (ATHE).
YTD Price Performance: 0%
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $39.1M
For an in-depth examination of ATH stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com